Cellmid (CDY) Stock Price, News & Analysis

Company Overview

Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CDY Stock Analysis - Frequently Asked Questions

How were Cellmid's earnings last quarter?

Cellmid Limited (ASX:CDY) issued its earnings results on Thursday, February, 21st. The company reported ($0.05) EPS for the quarter.

What other stocks do shareholders of Cellmid own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellmid investors own include Westgold Resources (WGX), WAM Research (WAX) and Credit Intelligence (CI1).

Company Calendar

• Last Earnings: 2/21/2019
• Today: 7/05/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:CDY
• CIK: N/A
• Web: www.cellmid.com.au
• Phone: 61 2 9221 6830
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 13.74
• Current Ratio: 5.89
• Quick Ratio: 4.45

Sales & Book Value

• Annual Sales: A$5.82 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 4.63
• Book Value: A$0.06 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 220,216,992
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A